In this captivating episode, we dive deep into the groundbreaking intersection of artificial intelligence and enzyme engineering with David Schönauer, founder and CEO of Aminoverse.
From university lab benches to pioneering AI-driven enzyme discovery, David shares how his startup is transforming the biotech landscape by making enzyme development faster, more predictable, and increasingly efficient.
Highlights:
Discover how AI is revolutionizing enzyme prediction and design, potentially reducing development time from years to weeks
Learn why high-quality wet lab data remains crucial for AI success in biotech, and how Aminoverse's unique approach combines both worlds
Gain insights into building a profitable biotech startup without massive venture capital funding, proving that sustainable growth is possible in deep tech
David's journey from academic researcher to biotech entrepreneur offers invaluable lessons for scientists considering the entrepreneurial path. His practical approach to combining cutting-edge AI with traditional wet lab techniques demonstrates how modern biotechnology can solve real-world problems while maintaining scientific rigor.
Ready to explore the future of biotech? Listen now to learn how AI is transforming enzyme engineering and what it means for the future of sustainable technology, pharmaceuticals, and more.
Ready to revolutionize your biologics development? Our Fractional CTO services help you develop better, faster, and more cost-effectively. Leverage your full potential today — book a free consultation at https://bruehlmann-consulting.com and let's accelerate your success!
Podden och tillhörande omslagsbild på den här sidan tillhör David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado. Innehållet i podden är skapat av David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado och inte av, eller tillsammans med, Poddtoppen.